Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Samuel Linford

Orthopaedic Surgery Afton, WY Medical Doctor

NPI 1306091046 CMS profile 1308461

120 Hospital Ln, Afton, WY 83110

Open in the dashboard

General payments

$7,635

48 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Samuel Linford of Afton, WY is reported in the CMS Open Payments database as having received $7,635 across 48 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $331 9
2024 General $3,023 16
2023 General $117 3
2022 General $3,839 14
2021 General $106 2
2020 General $14 1
2019 General $204 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Samuel Linford
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Samuel Linford were reported at $331. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Samuel Linford Orthopaedic Surgery median Middle half National median
2019 $204 $644 $140–$2,844 $163
2020 $14 $312 $75–$1,860 $114
2021 $106 $520 $117–$2,495 $132
2022 $3,839 $598 $128–$2,731 $149
2023 $117 $461 $128–$2,264 $160
2024 $3,023 $497 $134–$2,475 $164
2025 $331 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Zimmer Biomet Holdings, Inc. $3,356 20 payments
  2. Active Medical, LLC $2,172 2 payments
  3. Arthrex, Inc. $1,496 7 payments
  4. Heron Therapeutics, Inc. $170 3 payments
  5. Stryker Corporation $131 3 payments
  6. Anika Therapeutics, Inc. $85 1 payment
  7. Medacta USA, Inc. $37 1 payment
  8. Ferring Pharmaceuticals Inc. $33 2 payments
  9. Solventum Corporation $31 1 payment
  10. Encore Medical, LP $27 1 payment
  11. Other $96 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $3,016 7 payments
  2. Education $2,633 4 payments
  3. Food and Beverage $1,974 36 payments
  4. Debt forgiveness $12 1 payment
Products named General payments · program years 2019–2025
  1. Persona Knees $2,237 7 payments
  2. ZYNRELEF $170 3 payments
  3. Comprehensive Shoulder System $139 1 payment
  4. ROSA Knees $135 2 payments
  5. ROSA Knees $130 1 payment
  6. Comprehensive $120 1 payment
  7. Persona Knees $94 1 payment
  8. Vanguard $94 1 payment
  9. Tactoset $85 1 payment
  10. Integrity Implant $85 1 payment
  11. Other $571 22 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

46

Median for Orthopedic Surgery: 203

Drug cost

$424

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 23 $387
Amoxicillin Generic 23 $36

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$54,113

Of which drugs: $12,803

Medicare patients

109

Average age 74

Services billed

662

66 women, 43 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 66%
Diabetes 17%
Atrial fibrillation 17%
Chronic kidney disease 16%
Depression 14%
Heart failure 11%
Osteoporosis 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, gel-one, for intra-articular injection, per dose J7326 Office 21 32 $12,620
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 39 237 $181

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

48 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Wyoming

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record